Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Schering Sees Growth Opportunity For Organon Products In The U.S. – Hassan

Executive Summary

Schering-Plough sees significant growth potential for Organon's products that currently are marketed in the U.S., CEO Fred Hassan said March 20

You may also be interested in...



FTC investigating Schering/Organon merger

The Federal Trade Commission is requesting additional information from Schering-Plough regarding its planned acquisition of Akzo Nobel's pharmaceutical and animal health business, Organon Biosciences. Despite FTC's request, Schering continues to expect the $14.4 billion transaction to be completed by the end of 2007 (1"The Pink Sheet" March 26, 2007, p. 25)...

FTC investigating Schering/Organon merger

The Federal Trade Commission is requesting additional information from Schering-Plough regarding its planned acquisition of Akzo Nobel's pharmaceutical and animal health business, Organon Biosciences. Despite FTC's request, Schering continues to expect the $14.4 billion transaction to be completed by the end of 2007 (1"The Pink Sheet" March 26, 2007, p. 25)...

Schering Jumps On Organon Buy; Will Late-Stage M&A Keep Fueling Pharma?

Pharmaceutical companies unveiling mergers and acquisitions in the first quarter were among those rewarded by Wall Street

Related Content

UsernamePublicRestriction

Register

OM014079

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel